Home / Intelligence / Blog / Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Published August 30, 2021
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform designed to improve clinical trial execution, help research manage their clinical trials, and explore flexible study options for decentralized and hybrids trials as well as novel ways to capture real-world data (i.e., generated by novel sensors and biomarkers).
While many details of the agreement were not disclosed, including the financial terms, this deal could “set a new standard for clinical studies and evidence generation,” according to Amy Abernethy, MD, PhD, a former principal deputy commissioner at the FDA and current President of Clinical Studies Platforms at Verily. With a tech giant backing and a growing pipeline of digital technologies, including a virtual clinic that provides online care and coaching for chronic conditions, Verily can now use a new system to accelerate its research and trial processes, to quickly establish its presence in the DTx.
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
The Future of Patient Finding
November 13, 2024 | 1:00 – 1:45 PM ET
Two additional sessions will be offered: November 14 – 16:00 – 16:45 (UTC +8:00) – Asia/Shanghai November 14 – 15:00 – 15:45 CET – Europe/Berlin Patient finding is more than a buzzword. Ready to challenge the status quo? With more data, advancements in AIML and greater access to insights, it is not surprising that patient […]
Sign Up Now
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More